Trial Profile
A Safety and Clinical Efficacy Study Measuring Echocardiographic Composite Comparing Ambrisentan (Letairis) After a Switch From Bosentan (Tracleer) or Macintentan (Opsumit) in Treatment of Pulmonary Arterial Hypertension (PAH)
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Ambrisentan (Primary)
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- 05 Apr 2019 Status changed from recruiting to discontinued.
- 20 Sep 2016 New trial record